IBI322 is a recombinant anti-CD47/PD-L1 bispecific antibody developed by Innovent. As a class 1 innovative drug and a potentially first-in-class molecule, IBI322 can effectively induce the phagocytosis of tumor cells and stimulate the activation of T lymphocytes to exert anti-tumor activity. IBI...
Therefore, the balance between increasing antitumor efficacy and reducing potential toxicity of hematology especially anemia is one of the key issues for CD47 targeted drug development and clinical application. Table 1. The development of anti-CD47/SIRPα therapies in clinical trials. NameComposition...